Fate tracking reveals differences between Reelin + hepatic stellate cells ( HSCs) and Desmin + HSCs in activation, migration and proliferation
Cell Proliferation · 2023
DOI: 10.1111/cpr.13500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2023. Verfasst von Ning Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine/Bio-medical Center/, Huazhong Agricultural University, Wuhan, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Plan, National Natural Science Foundation of China.
Abstract (Originalsprache)
The activation of hepatic stellate cells (HSCs) is the main cause of liver fibrogenesis in response to different etiologies of chronic liver injuries. HSCs are heterogeneous, but the lack of specific markers to distinguish different HSC subset hinders the development of targeted therapy for liver fibrosis. In this study, we aim to reveal new HSC subsets by cell fate tracking. We constructed a novel ReelinCreERT2 transgenic mouse model to track the fate of cells expressing Reelin and their progeny (Reelin + cells). And we investigated the property of Reelin + cells, such as differentiation and proliferation, in hepatotoxic (carbon tetrachloride; CCl 4 ) or cholestatic (bile duct ligation; BDL) liver injury models by immunohistochemistry. Our study revealed that Reelin + cells were a new HSC subset. In terms of activation, migration, and proliferation, Reelin + HSCs displayed different properties from Desmin + HSCs (total HSCs) in cholestatic liver injury model but shared similar properties to total HSCs in hepatotoxic liver injury model. Besides, we did not find evidence that Reelin + HSCs transdifferentiated into hepatocytes or cholangiocytes through mesenchymal‐epithelial transition (MET). In this study, our genetic cell fate tracking data reveal that ReelinCreERT2‐labelled cells are a new HSC subset, which provides new insights into targeted therapy for liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine/Bio-medical Center/, Huazhong Agricultural University, Wuhan, China.
- College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
- Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China.
- Department of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou, China.
ORCID-Profile: Ning Chen
Förderung
- National Key R&D Plan
- National Natural Science Foundation of China
Zitieren
APA
Chen, N., Liu, S., Qin, D., Guan, D., Chen, Y., Hou, C., Zheng, S., Wang, L., Chen, X., Chen, W., & Zhang, L. (2023). Fate tracking reveals differences between Reelin + hepatic stellate cells ( HSCs) and Desmin + HSCs in activation, migration and proliferation. Cell Proliferation. https://doi.org/10.1111/cpr.13500
Vancouver
Chen N, Liu S, Qin D, Guan D, Chen Y, Hou C, et al. Fate tracking reveals differences between Reelin + hepatic stellate cells ( HSCs) and Desmin + HSCs in activation, migration and proliferation. Cell Proliferation. 2023. doi:10.1111/cpr.13500
BibTeX
@article{Chen2023,
author = {Chen, Ning and Liu, Shenghui and Qin, Dan and Guan, Dian and Chen, Yaqing and Hou, Chenjiao and Zheng, Songyun and Wang, Liqiang and Chen, Xiangmei and Chen, Wei and Zhang, Lisheng},
title = {Fate tracking reveals differences between Reelin + hepatic stellate cells ( HSCs) and Desmin + HSCs in activation, migration and proliferation},
journal = {Cell Proliferation},
year = {2023},
doi = {10.1111/cpr.13500}
}
EUVIMED